Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DRMA NASDAQ:DRRX NASDAQ:GELS NASDAQ:VYNE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRMADermata Therapeutics$6.45+3.5%$0.81$5.74▼$37.90$3.97M0.56189,143 shs97,087 shsDRRXDURECT$1.84-1.9%$0.70$0.48▼$2.64$58.05M0.822.74 million shs859,880 shsGELSGelteq$1.62-6.4%$1.82$0.77▼$5.50$16.33MN/A189,349 shs66,557 shsVYNEVYNE Therapeutics$0.35-3.5%$1.14$0.34▼$4.30$5.56M1.762.79 million shs2.94 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRMADermata Therapeutics+934.98%+822.48%+867.02%+641.46%+275.00%DRRXDURECT-1.87%+223.41%+175.28%+206.86%+12.58%GELSGelteq-6.36%-15.18%-7.43%-12.43%+161,999,900.00%VYNEVYNE Therapeutics-3.47%-75.83%-76.63%-74.24%-81.43%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDRMADermata Therapeutics0.4806 of 5 stars1.53.00.00.00.60.80.0DRRXDURECT1.0383 of 5 stars0.03.00.04.42.40.00.0GELSGelteqN/AN/AN/AN/AN/AN/AN/AN/AVYNEVYNE Therapeutics2.5133 of 5 stars3.05.00.00.01.41.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDRMADermata Therapeutics 3.00Buy$3.00-53.49% DownsideDRRXDURECT 2.00HoldN/AN/AGELSGelteq 0.00N/AN/AN/AVYNEVYNE Therapeutics 2.00Hold$6.251,671.04% UpsideCurrent Analyst Ratings BreakdownLatest DRMA, GELS, VYNE, and DRRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/31/2025VYNEVYNE TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral7/30/2025VYNEVYNE TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/30/2025VYNEVYNE TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/21/2025DRMADermata TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $3.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDRMADermata TherapeuticsN/AN/AN/AN/A$0.62 per shareN/ADRRXDURECT$2.03M28.06N/AN/A$0.29 per share6.33GELSGelteq$100K152.93N/AN/A$1.30 per share1.25VYNEVYNE Therapeutics$500K10.74N/AN/A$3.53 per share0.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDRMADermata Therapeutics-$12.29M-$16.41N/A∞N/AN/A-270.81%-179.96%8/6/2025 (Estimated)DRRXDURECT-$8.32M-$0.15N/AN/AN/A-91.54%-267.36%-64.00%8/12/2025 (Estimated)GELSGelteq-$2.33MN/A0.00∞N/AN/AN/AN/AN/AVYNEVYNE Therapeutics-$39.83M-$0.99N/AN/AN/A-6,974.55%-71.89%-58.94%8/13/2025 (Estimated)Latest DRMA, GELS, VYNE, and DRRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025VYNEVYNE Therapeutics-$0.24N/AN/AN/A$0.15 millionN/A8/12/2025Q2 2025DRRXDURECT-$0.13N/AN/AN/A$0.32 millionN/A5/14/2025Q1 2025DRMADermata Therapeutics-$0.45-$0.45N/A-$0.45N/AN/A5/8/2025Q1 2025VYNEVYNE Therapeutics-$0.29-$0.20+$0.09-$0.20$0.05 million$0.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDRMADermata TherapeuticsN/AN/AN/AN/AN/ADRRXDURECTN/AN/AN/AN/AN/AGELSGelteqN/AN/AN/AN/AN/AVYNEVYNE TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDRMADermata TherapeuticsN/A3.703.70DRRXDURECTN/A1.231.22GELSGelteqN/A0.79N/AVYNEVYNE TherapeuticsN/A4.474.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDRMADermata Therapeutics8.67%DRRXDURECT28.03%GELSGelteqN/AVYNEVYNE Therapeutics83.78%Insider OwnershipCompanyInsider OwnershipDRMADermata Therapeutics18.50%DRRXDURECT3.20%GELSGelteqN/AVYNEVYNE Therapeutics4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDRMADermata Therapeutics86.38 million5.20 millionNot OptionableDRRXDURECT8031.04 million30.05 millionOptionableGELSGelteqN/A9.44 millionN/AN/AVYNEVYNE Therapeutics3015.21 million14.48 millionNot OptionableDRMA, GELS, VYNE, and DRRX HeadlinesRecent News About These CompaniesVYNE Therapeutics (NASDAQ:VYNE) Lowered to "Neutral" Rating by HC Wainwright1 hour ago | americanbankingnews.comHere's Why VYNE Therapeutics (NASDAQ:VYNE) Must Use Its Cash WiselyAugust 1 at 4:19 AM | finance.yahoo.comRepibresib gel fails to meet endpoints for nonsegmental vitiligo studyAugust 1 at 4:19 AM | healio.comHVyne Therapeutics Ends Trial of Repibresib Gel in Nonsegmental VitiligoJuly 31 at 3:02 AM | marketwatch.comVYNE Therapeutics stock falls after vitiligo trial fails to meet endpointsJuly 31 at 3:02 AM | za.investing.comHC Wainwright & Co. Downgrades VYNE Therapeutics (VYNE)July 31 at 3:02 AM | msn.comVYNE Ends Phase IIb Vitiligo Trial of Repibresib After Missing Primary EndpointJuly 31 at 3:02 AM | appliedclinicaltrialsonline.comAVYNE Therapeutics Shares Sink Premarket Following End to Trial After Endpoint MissedJuly 31 at 3:02 AM | marketwatch.comVyne's lead BET inhibitor fails phase 2 vitiligo trial, sinking stockJuly 31 at 3:02 AM | fiercebiotech.comFVyne Hit With Downgrades After Repibresib Misses Endpoints In Vitiligo Trial; Traders Still Eye ReboundJuly 31 at 3:02 AM | msn.comVYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental VitiligoJuly 30 at 8:00 AM | globenewswire.comVYNE Therapeutics (NASDAQ:VYNE) Shares Down 0.7% - Here's What HappenedJuly 30 at 2:39 AM | americanbankingnews.comVyne Therapeutics: A Risky Bet On Upcoming Vitiligo Ph2b ReadoutJuly 28, 2025 | seekingalpha.comVYNE Therapeutics Inc. (VYNE) Gets Buy Reaffirmation on Pipeline ProgressJuly 11, 2025 | insidermonkey.comVyne prunes psoriasis trial under FDA hold, but keeps faith in BET inhibitorJuly 2, 2025 | fiercebiotech.comFVYNE Therapeutics Provides Update on VYN202 Program Following FDA Clinical Hold for Psoriasis TrialJuly 2, 2025 | quiverquant.comQVYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202July 2, 2025 | globenewswire.comVYNE Stock Touches 52-Week Low at $0.96 Amid Market ChallengesMay 31, 2025 | investing.comVYNE Therapeutics First Quarter 2025 Earnings: Beats ExpectationsMay 12, 2025 | finance.yahoo.comVYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business UpdateMay 8, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDRMA, GELS, VYNE, and DRRX Company DescriptionsDermata Therapeutics NASDAQ:DRMA$6.45 +0.22 (+3.50%) Closing price 08/1/2025 03:55 PM EasternExtended Trading$6.54 +0.09 (+1.40%) As of 08/1/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.DURECT NASDAQ:DRRX$1.84 -0.04 (-1.87%) As of 08/1/2025 04:00 PM EasternDURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.Gelteq NASDAQ:GELS$1.62 -0.11 (-6.36%) As of 08/1/2025 04:00 PM EasternGelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.VYNE Therapeutics NASDAQ:VYNE$0.35 -0.01 (-3.47%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.36 +0.00 (+0.60%) As of 08/1/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
